These observations indicate that mutations in SAMHD1 are rather important to drive CLL relapse and/or impede CLL chemo-immunotherapy, than for early events during CLL onset/progression. This evidence concerns the gene SAMHD1 and B-cell chronic lymphocytic leukemia.